To include your compound in the COVID-19 Resource Center, submit it here.

AnaptysBio plans study of first-in-class IL-36R antagonist

Antibody platform company AnaptysBio Inc. (San Diego, Calif.)

Read the full 84 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE